Table 2

Number of metastases in EB 1089- and placebo-treated Gγ/T-15 transgenic mice

TreatmentStart (wk)aNo. of micebNo. of metastasesc
Placebo1491.89 (0.6)
EB 1089
 0.572.29 (1.1)
 252.40 (0.5)
 3101.60 (0.5)
 481.50 (1.1)
 562.17 (0.8)
 1050.80 (0.4)d
Placebo1171.86 (0.4)
EB 1089
 0.552.20 (1.1)
 262.00 (0.6)
 391.89 (0.6)
 4121.67 (0.9)
Placebo972.29 (1.3)
EB 1089
 2102.00 (1.2)
  • a Age of Gγ/T-15 mice when treatment began.

  • b Gγ/T-15 mice with prostate tumors treated for 21 days with placebo or EB 1089.

  • c Number of visible metastatic lesions (lymph node, adrenal, and kidney) per mouse. Number in the parentheses is SD.

  • d Significant difference: P < 0.005, two-tailed Student’s t test.